Ionis Pharmaceuticals IONS AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's AFS securities?
- Ionis Pharmaceuticals (IONS) reported AFS securities of $630.67M in Q1 2026.
- How has Ionis Pharmaceuticals's AFS securities changed year-over-year?
- Ionis Pharmaceuticals's AFS securities decreased by 7.4% year-over-year, from $681.35M to $630.67M.
- What is the long-term trend for Ionis Pharmaceuticals's AFS securities?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's AFS securities has grown at a 5.1% compound annual growth rate (CAGR), from $635.12M to $773.71M.
- What does AFS securities mean?
- The total market value of all debt and equity investments classified as available-for-sale.
- How do you interpret AFS securities?
- An increase reflects growth in the company's investment portfolio, while a decrease may indicate asset liquidation to fund operations.
- How does AFS securities compare across companies?
- Commonly used by pharmaceutical companies to manage cash reserves generated from licensing deals or equity raises.